Go to Page # Page of 55
loading

Topline Results Alirocumab in Patients After Acute Coronary Syndrome

 Gregory G. Schwartz, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Diaz, Jay Edelberg, Shaun
  26th-Jun-2018
Description: Alirocumab, versus placebo, reduces cardiovascular (CV) morbidity and mortality after recent acute coronary syndrome (ACS) in patients with elevated levels of atherogenic lipoproteins despite intensive or maximumtolerated statin therapy.
Views: 3204
Domain: Medical
Category: Biotech/Pharma
Contents:
The ODYSSEY OUTCOMES Trial: Topline Results

Alirocumab in Patients After Acute Coronary Syndrome
Gregory G. Schwartz, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Diaz, Jay Edelberg,
Shaun G. Goodman, Corinne Hanotin, Robert Harrington, J. Wouter Jukema,
Guillaume Lecorps, Angèle Moryusef, Robert Pordy, Matthew Roe, Harvey D. White, Andreas Zeiher,
Ph. Gabriel Steg
On behalf of th ... See more

Recent Presentations

...
01 October, 2019
...
30 September, 2019
OHWRC
28 September, 2019